What is Curemark?
Curemark, LLC, through its wholly-owned subsidiary Galenagen LLC, is dedicated to advancing treatments for a range of neurological and infectious diseases. Galenagen focuses on antibacterial and antiviral solutions, alongside medical devices, while Curemark's core mission involves developing therapies for conditions including autism, ADHD, addiction, schizophrenia, and Parkinson's disease. The company's strategic positioning in the biopharmaceutical sector, particularly in neurotherapeutics, highlights its commitment to addressing unmet medical needs through innovative research and development.
How much funding has Curemark raised?
Curemark has raised a total of $67.7M across 9 funding rounds:
Debt
$6M
Private Equity
$18.5M
Debt
$5M
Private Equity
$20.3M
Private Equity
$3M
Private Equity
$3.2M
Debt
$150K
Debt (2012): $6M, investors not publicly disclosed
Private Equity (2013): $18.5M, investors not publicly disclosed
Debt (2014): $5M, investors not publicly disclosed
Private Equity (2015): $20.3M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
Private Equity (2018): $3.2M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Curemark
PPP
Public-Private Partnership
What's next for Curemark?
With the recent infusion of major strategic capital, Curemark is poised to advance its preclinical and clinical-stage programs. The enterprise-level backing suggests a focus on scaling operations and potentially bringing its pipeline therapies closer to market. This investment will likely fuel further research, clinical trials, and regulatory submissions, aiming to solidify Curemark's position in the competitive biopharmaceutical landscape. The company's trajectory indicates a strong emphasis on innovation and addressing complex neurological and infectious disease challenges.
See full Curemark company page
